Sensome Begins Human Trial for Its AI-Powered Stroke Guidewire
13.9.2021 09:00:00 EEST | Business Wire | Press release
Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that Gold Coast University Hospital (GCUH) in Australia enrolled the first patients in the Company’s CLOT OUT first-in-human study evaluating safety and performance of the Clotild® Smart Guidewire System in large-vessel acute ischemic stroke patients.
Acute ischemic stroke, a leading cause of long-term disability, can be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices, which are guided from the wrist or groin over a wire to the blockage. To improve patient prognosis, the clot needs to be removed as fast as possible. Today, without knowledge of the clot’s characteristics, the clot can only be removed on the first attempt in one out of three cases. Clotild® Smart Guidewire System integrating Sensome’s AI-powered tissue sensor enables the guidewire to provide physicians with critical information on the clot.
“Endovascular thrombectomy is no longer just about removing the clot. To get the best result for your patient, you need to get the clot out with complete revascularization the first time,” explains Dr Hal Rice, Director of Interventional Neuroradiology at GCUH, “The Clotild® guidewire is the first device that promises to provide live real time information during the intervention that can help increase our chances to choose the right interventional approach from the get-go.”
“Evidence has been mounting over the past few years that factors like the biological clot composition should be considered when choosing the fastest method to remove a clot,” indicates Dr Andrew Cheung, co-coordinating Investigator of the study with Dr Dennis Cordato, both at the Liverpool Hospital in New South Wales, Australia, “The CLOT OUT trial aims to demonstrate that using Clotild® in humans is safe and can detect clot composition.”
“After seven years of intense R&D we are now starting a new chapter,” emphasizes Franz Bozsak, CEO and co-founder of Sensome, “We are very excited to work with an exceptional team of investigators to achieve our goal of making a difference for large-vessel acute ischemic stroke patients.”
CLOT OUT is a multicenter, prospective trial intended to take place in leading stroke centers across Australia, Belgium and France and aims to enroll up to 100 patients. Data from the first cases will be presented at this year’s prestigious international LINNC Conference in Paris and interactive online stroke event SLICE Worldwide.
About Sensome
Sensome, a spin-off from CNRS and Ecole polytechnique (France), has developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues with unequaled predictive reliability. Its first application is the Clotild® connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210912005010/en/
Contact information
For more information, please contact Franz Bozsak, press@sensome.com or +33 1 85 37 07 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Defines Its Role as the Technology Behind Better Decisions in the AI Era7.4.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a renewed brand identity that reflects its role in empowering organizations to make better decisions in complex, high-stakes environments. As organizations increasingly rely on optimization to put their AI-driven insights into action, the Gurobi Optimizer is a foundational component of decision intelligence systems, where different approaches to AI—from prediction to optimization—work together to guide business outcomes. “AI has transformed how organizations generate insight, but insight alone does not drive outcomes—decisions do,” said Duke Perrucci, CEO, Gurobi. “We see optimization as the GPS for AI, enabling users to determine the best possible course of action in complex environments. Those decisions are what drive real outcomes, and we’re proud to be the technology behind them.” Across industries such as energy, supply chain management, manufacturing, and finance, organizations trust Gurobi
Poland's Galaxy Systemy Informatyczne Becomes First Private Enterprise to Buy Quantum Computer from IQM7.4.2026 16:00:00 EEST | Press release
IQM Quantum Computers, a global leader in superconducting quantum computing, today announced a commercial milestone to deploy a hybrid integrated quantum computer at GalaxySystemy Informatyczne Sp. z o.o., marking its first deployment in a private enterprise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407351934/en/ IQM Radiance quantum computer Galaxy has been implementing innovations in security, digitisation, and hardware infrastructure while providing IT solutions, supporting HPC infrastructure to shape Poland’s economy based on data and artificial intelligence. The 54-qubit Radiance system will also be the most advanced quantum computer in Poland, and Galaxy, a provider of technological solutions, will become the first private company in the world to own and operate such quantum infrastructure. The system, which will be installed at Galaxy’s headquarters in Zielona Góra in the fourth quarter of 2026, wil
Cessna SkyCourier Strengthens Mission Versatility With New In‑Flight Operable Door Option7.4.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced a new In-Flight Operable Door option for the passenger variant of its twin-engine, large-utility Cessna SkyCourier turboprop, expanding the aircraft’s Special Mission versatility for military, humanitarian and commercial operations. The functionality is expected to be available as a Special Mission factory-installed option in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407228562/en/ Mission flexibility starts at the Cessna SkyCourier door “An In-Flight Operable Door builds on the Cessna SkyCourier’s reputation for reliability and adaptability, reinforcing its role as a purpose-built solution for high-demand missions,” said Bob Gibbs, vice president, Special Missions Sales. “The option opens new opportunities for customers worldwide, including armed forces, smokejumpers, disaster relief groups and commercial skydiving operators.” The Cessna
Peruvian Army Selects Beechcraft King Air 360C for Multi-Mission Operation7.4.2026 16:00:00 EEST | Press release
The Peruvian Army has signed an agreement to purchase a cargo door equipped Beechcraft King 360C aircraft, which is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, to deliver critical services for communities across the country. With its generous payload, the twin-engine turboprop will enhance the Army’s capability to perform medical evacuations, transport patients and provide rapid humanitarian aid during disaster relief efforts. The aircraft is expected to enter service in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407176246/en/ Beechcraft King Air 360C supporting the Peruvian Army’s emergency response, medical evacuation and disaster relief missions This order follows the delivery of two multi-mission, air medical equipped Beechcraft King Air 360CHW aircraft to the Peruvian Air Force. The King Air 360CHW is cargo door equipped and fitted for operation at higher operating
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery7.4.2026 16:00:00 EEST | Press release
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities. “Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.” Enki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom